SCHEMBL2139648

SCHEMBL2139648

O=C1c2c([N+](=O)[O-])cc([N+](=O)[O-])c(O)c2C(=O)c2c(O)c([N+](=O)[O-])cc([N+](=O)[O-])c21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.55
HIF1A Q16665 2/20 0.55
TP53 P04637 1/20 0.55
CYP3A4 P08684 1/20 0.55
TSHR P16473 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GPR35 Q9HC97 8/20 0.52
CA12 O43570 3/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA9 Q16790 3/20 0.48
ALDH1A1 P00352 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
TTR P02766 1/20 0.47
CYP1A2 P05177 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29718898 1.00 HPGD (0.55) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL28592683 0.82 HPGD (0.50) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL30195179 0.82 HPGD (0.50) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL848253 0.82 GPR35 (0.53) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL849411 0.82 HPGD (0.50) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL30118000 0.82 HPGD (0.40) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL11807919 0.80 HPGD (0.47) HPGDHIF1ATP53CYP3A4TSHR
SCHEMBL11245341 0.80 HPGD (0.47) HPGDHIF1ATP53CYP3A4TSHR
Potassium Ion SCHEMBL11818734 0.78 HPGD (0.46) HPGDHIF1ATP53CYP3A4TSHR
Potassium Ion SCHEMBL11820275 0.78 HPGD (0.46) HPGDHIF1ATP53CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103025340-B Aloe vera composition and its use in preparing medicaments for anti-viral and treating Acquired Immune Deficiency Syndrome (AIDS) NORTH TEXAS MEDICAL ASS 2014-12-24 CN claimed
CN-103025340-A Antiviral properties of Aloe vera and treatment of Acquired Immune Deficiency Syndrome (AIDS) NORTH TEXAS MEDICAL ASS 2013-04-03 CN claimed
EP-1808169-B1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTEOTECH INC (US) 2012-05-30 EP claimed
JP-4370072-B2 2009-11-25 JP claimed
US-20070191330-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTEOTECH, INC. 2007-08-16 US claimed
EP-1808169-A2 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases Proteotech Inc. (US) 2007-07-18 EP claimed
US-20040152760-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2004-08-05 US claimed
JP-2003532634-A 2003-11-05 JP claimed
EP-1244435-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES Proteotech Inc. (US) 2002-10-02 EP claimed
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2001-11-29 US claimed
WO-2001049281-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES PROTEOTECH, INC. (US) 2001-07-12 WO claimed
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2026-04-30 US disclosed
EP-4593631-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME Mars, Incorporated (US) 2025-08-06 EP disclosed
WO-2024073025-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2024-04-04 WO disclosed
EP-4344552-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2024-04-03 EP disclosed
EP-0655971-A1 PARTICLE BINDERS WEYERHAEUSER COMPANY (US) 1995-06-07 EP disclosed
WO-1994004352-A1 PARTICLE BINDERS WEYERHAEUSER COMPANY (US) 1994-03-03 WO disclosed
WO-1994004351-A1 PARTICLE BINDING TO FIBERS WEYERHAEUSER COMPANY (US) 1994-03-03 WO disclosed
US-4859784-A Process for the production of optically active cyanohydrins DEGUSSA AKTIENGESELLSCHAFT (DE) 1989-08-22 US disclosed
EP-0134198-A1 Use of quinone derivatives for the protection of cultivated plants against the phytotoxic effects of herbicides CIBA-GEIGY AG (CH) 1985-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191330-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT HPGD 1877/4885HIF1A 2215/4885TP53 820/4885
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT HPGD 1873/4885HIF1A 2301/4885TP53 818/4885
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME PIGS, TAS2R13, CEL HPGD 4694/4885HIF1A 889/4885TP53 3198/4885
US-20040152760-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT HPGD 1873/4885HIF1A 2301/4885TP53 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.